JP2023507408A5 - - Google Patents
Info
- Publication number
- JP2023507408A5 JP2023507408A5 JP2022537311A JP2022537311A JP2023507408A5 JP 2023507408 A5 JP2023507408 A5 JP 2023507408A5 JP 2022537311 A JP2022537311 A JP 2022537311A JP 2022537311 A JP2022537311 A JP 2022537311A JP 2023507408 A5 JP2023507408 A5 JP 2023507408A5
- Authority
- JP
- Japan
- Prior art keywords
- less
- approximately
- dose
- pabra
- agonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962950077P | 2019-12-18 | 2019-12-18 | |
| US62/950,077 | 2019-12-18 | ||
| US202063034364P | 2020-06-03 | 2020-06-03 | |
| US63/034,364 | 2020-06-03 | ||
| PCT/US2020/065655 WO2021127210A1 (en) | 2019-12-18 | 2020-12-17 | Methods for improving neurological diseases and disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023507408A JP2023507408A (ja) | 2023-02-22 |
| JP2023507408A5 true JP2023507408A5 (https=) | 2023-12-08 |
| JP7744344B2 JP7744344B2 (ja) | 2025-09-25 |
Family
ID=76437605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022537311A Active JP7744344B2 (ja) | 2019-12-18 | 2020-12-17 | 神経系疾患および障害を改善するための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US11607395B2 (https=) |
| EP (1) | EP4076422A4 (https=) |
| JP (1) | JP7744344B2 (https=) |
| AU (1) | AU2020405091B2 (https=) |
| CA (1) | CA3161376A1 (https=) |
| WO (1) | WO2021127210A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3161376A1 (en) | 2019-12-18 | 2021-06-24 | Anthony P. FORD | Methods for improving neurological diseases and disorders |
| WO2022051305A1 (en) * | 2020-09-01 | 2022-03-10 | Curasen Therapeutics, Inc. | Compositions and methods for improving neurological diseases and disorders |
| CN115212194B (zh) * | 2022-01-07 | 2024-08-13 | 中南大学湘雅三医院 | 纳多洛尔在制备治疗缺血/再灌注损伤药物及细胞保护药物中的应用 |
| CN116212002A (zh) * | 2022-01-14 | 2023-06-06 | 中南大学湘雅三医院 | 一种预防或治疗缺血/再灌注损伤的药物组合物及应用 |
| GB202205895D0 (en) | 2022-04-22 | 2022-06-08 | Atrogi Ab | New medical uses |
| US20250134835A1 (en) * | 2022-05-17 | 2025-05-01 | Curasen Therapeutics, Inc. | Compositions and methods for treating patients with amyotrophic lateral sclerosis (als) |
| WO2024137478A1 (en) * | 2022-12-21 | 2024-06-27 | Curasen Therapeutics, Inc. | Methods for treating various conditions and indications with agonists and antagonists |
| EP4651867A1 (en) | 2023-01-20 | 2025-11-26 | Atrogi AB | Beta 2-adrenergic receptor agonists for treatment or prevention of muscle wasting |
| GB202302225D0 (en) | 2023-02-16 | 2023-04-05 | Atrogi Ab | New medical uses |
| GB202303229D0 (en) | 2023-03-06 | 2023-04-19 | Atrogi Ab | New medical uses |
| GB202403169D0 (en) | 2024-03-05 | 2024-04-17 | Atrogi Ab | New medical uses |
| WO2025188807A1 (en) * | 2024-03-06 | 2025-09-12 | Curasen Therapeutics, Inc. | Combination compositions and methods of use |
| WO2025238248A1 (en) | 2024-05-17 | 2025-11-20 | Atrogi Ab | USE OF β2-ADRENERGIC RECEPTOR AGONISTS IN TREATING MUSCLE WASTING |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5541188A (en) | 1987-09-15 | 1996-07-30 | The Rowett Research Institute | Therapeutic applications of beta-adrenergic agonists |
| CA2715683A1 (en) | 1999-08-21 | 2001-03-01 | Nycomed Gmbh | Synergistic combination |
| US7135497B1 (en) | 2000-07-07 | 2006-11-14 | New York Medical College | Treating neural conditions resulting from spinal cord contusions and other causes |
| AU2003251949A1 (en) | 2002-07-18 | 2004-02-09 | Vanderbilt University | Therapeutic and screening methods employing partial agonism of the alpha-2a adrenergic receptor subtype |
| EP1677778A2 (en) | 2003-10-09 | 2006-07-12 | Inverseon, Inc. | Method of treating airway diseases with beta-adrenergic inverse agonists |
| US9492114B2 (en) | 2004-06-18 | 2016-11-15 | Banner Health Systems, Inc. | Accelerated evaluation of treatments to prevent clinical onset of alzheimer's disease |
| US7528175B2 (en) | 2004-10-08 | 2009-05-05 | Inverseon, Inc. | Method of treating airway diseases with beta-adrenergic inverse agonists |
| EP1754474A1 (en) * | 2005-02-02 | 2007-02-21 | Eucro European Contract Research GmbH & Co. KG | Use of S-Clenbuterol |
| US20080033027A1 (en) | 2005-03-21 | 2008-02-07 | Vicus Therapeutics Spe 1, Llc | Drug combination pharmaceutical compositions and methods for using them |
| CN101203214B (zh) | 2005-04-13 | 2012-11-21 | 艾升制药公司 | 用于治疗皮肤结缔组织疾病的β2-肾上腺素受体激动剂 |
| US20070021421A1 (en) | 2005-07-25 | 2007-01-25 | Hampton Thomas G | Measurement of gait dynamics and use of beta-blockers to detect, prognose, prevent and treat amyotrophic lateral sclerosis |
| CN101300012B (zh) * | 2005-09-01 | 2011-09-14 | 弗·哈夫曼-拉罗切有限公司 | 作为p2x3和p2x2/3调节剂的二氨基嘧啶类化合物在制备治疗呼吸系统疾病的药物中的应用 |
| US20110046090A1 (en) | 2005-10-31 | 2011-02-24 | Braincells Inc. | Modulation of neurogenesis with gaba agents and gaba analogs |
| CN1991364A (zh) * | 2005-12-26 | 2007-07-04 | 中国科学院上海生命科学研究院 | 预防和治疗阿尔兹海默症的g蛋白偶联受体拮抗剂 |
| CA2732513C (en) * | 2008-08-01 | 2017-04-25 | Arca Biopharma, Inc. | Methods and compositions involving (s)-bucindolol |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| WO2011133226A2 (en) * | 2010-04-22 | 2011-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | Method for enhancing learning and memory impaired by neurodegenerative disorders and compounds and compositions for effecting the same |
| CN103561722A (zh) | 2011-04-13 | 2014-02-05 | 利发利希奥公司 | 用于抑制和／或调整炎性神经变性疾病中涉及到的效应t细胞的组合物和方法 |
| US9784001B1 (en) | 2011-05-03 | 2017-10-10 | Paul Kristen, Inc | Adjustable scaffolding suspension assembly |
| WO2013061161A2 (en) * | 2011-10-28 | 2013-05-02 | Green Bcn Consulting Services Sl | New combination therapies for treating neurological disorders |
| US9320724B2 (en) * | 2013-02-13 | 2016-04-26 | The Board Of Trustees Of The Leland Stanford Junior University | Method of improving cognition and increasing dendritic complexity in humans with down syndrome and compositions therefor |
| US20140256822A1 (en) | 2013-03-11 | 2014-09-11 | Pharmaceutical Productions Inc. | Transmucosal drug delivery system |
| WO2014210544A2 (en) | 2013-06-27 | 2014-12-31 | Cedars-Sinai Medical Center | Adrenoceptors antagonists for the prevention and treatment of neurodegenerative conditions |
| CN105473545B (zh) | 2013-07-08 | 2017-08-04 | 奥斯拜客斯制药有限公司 | 二羟苯基神经递质化合物、组合物以及方法 |
| JP2017505826A (ja) | 2014-02-18 | 2017-02-23 | ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ | 神経学的障害を有するヒトにおいて認知および社会的行動を改善するための化合物 |
| ES2864079T3 (es) * | 2014-05-30 | 2021-10-13 | Pfizer | Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos |
| US9889087B2 (en) | 2014-06-10 | 2018-02-13 | The Board Of Trustees Of The Leland Stanford Junior University | Intranasal delivery of β2-adrenergic receptor agonists for improving cognition in humans with down syndrome and compositions therefor |
| US10195198B2 (en) * | 2014-07-03 | 2019-02-05 | Afferent Pharmaceuticals, Inc. | Methods and compositions for treating diseases and conditions |
| TWI799849B (zh) * | 2015-04-24 | 2023-04-21 | 美商安美基公司 | 治療或預防偏頭痛之方法 |
| US11026942B2 (en) | 2015-12-29 | 2021-06-08 | Kyoto University | Agent for preventing and/or treating Alzheimer's disease |
| WO2017197324A1 (en) | 2016-05-13 | 2017-11-16 | The Board Of Trustees Of The Leland Stanford Junior University | Adrenergic receptor modulating compounds and methods of using the same |
| WO2018195473A1 (en) | 2017-04-20 | 2018-10-25 | The Brigham And Women's Hospital, Inc. | Combinations including beta-adrenoreceptor agonists for treatment of parkinson's disease and movement disorders |
| EP3806957A4 (en) * | 2018-06-14 | 2022-03-16 | Curasen Therapeutics, Inc. | METHODS OF DIAGNOSIS, MONITORING AND TREATMENT OF NEUROLOGICAL DISEASES AND DISORDERS |
| JP7682097B2 (ja) * | 2019-03-27 | 2025-05-23 | キュラセン セラピューティクス インコーポレイテッド | ベータアドレナリンアゴニスト及びそれを使用する方法 |
| WO2021081292A1 (en) | 2019-10-25 | 2021-04-29 | Curasen Therapeutics, Inc. | METHODS FOR TREATING NEUROLOGICAL DISORDERS WITH α1A-AR PARTIAL AGONISTS |
| CA3161376A1 (en) | 2019-12-18 | 2021-06-24 | Anthony P. FORD | Methods for improving neurological diseases and disorders |
| MX2022015165A (es) | 2020-06-04 | 2023-03-01 | Curasen Therapeutics Inc | Formas y composiciones de un agonista beta adrenégico. |
| US20250134835A1 (en) * | 2022-05-17 | 2025-05-01 | Curasen Therapeutics, Inc. | Compositions and methods for treating patients with amyotrophic lateral sclerosis (als) |
-
2020
- 2020-12-17 CA CA3161376A patent/CA3161376A1/en active Pending
- 2020-12-17 US US17/125,741 patent/US11607395B2/en active Active
- 2020-12-17 JP JP2022537311A patent/JP7744344B2/ja active Active
- 2020-12-17 AU AU2020405091A patent/AU2020405091B2/en active Active
- 2020-12-17 EP EP20902094.0A patent/EP4076422A4/en active Pending
- 2020-12-17 WO PCT/US2020/065655 patent/WO2021127210A1/en not_active Ceased
-
2023
- 2023-02-09 US US18/107,886 patent/US12558325B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023507408A5 (https=) | ||
| JP2021527712A5 (https=) | ||
| Bakshi et al. | High‐resolution fluorodeoxyglucose positron emission tomography shows both global and regional cerebral hypometabolism in multiple sclerosis | |
| JP7744344B2 (ja) | 神経系疾患および障害を改善するための方法 | |
| SOCIAL | Non-pharmacological intervention for dementia patients | |
| US20040122090A1 (en) | Methods for treating neuropsychiatric disorders with nmda receptor antagonists | |
| JP7265990B2 (ja) | 神経変性疾患あるいは認知機能障害の予防または治療剤としてのｒ－ケタミンおよびその誘導体 | |
| JP2004515477A (ja) | Ｎｍｄａレセプターアンタゴニストを用いて神経精神医学的障害を処置するための方法 | |
| Tsuchiya et al. | Rapidly progressive aphasia and motor neuron disease: a clinical, radiological, and pathological study of an autopsy case with circumscribed lobar atrophy | |
| US20120123164A1 (en) | Combinations of Eszopiclone and Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-N-Methyl-1-Napthalenamine or Trans 4-(3,4-Dichlorophenyl)-1,2,3,4-Tetrahydro-1-Napthalenamine, and Methods of Treatment of Menopause and Mood, Anxiety, and Cognitive Disorders | |
| JPH08500093A (ja) | 光学的に純粋な（−）シブトラミンを用いるうつ病およびその他の障害を治療する方法ならびに組成物 | |
| JP2021527711A5 (https=) | ||
| JP2023541379A5 (https=) | ||
| CA2139000A1 (en) | Methods and compositions for treating depression and other disorders using optically pure(+) sibutramine | |
| JP2025163203A (ja) | ドーパミン作動性ｃｎｓ障害の治療におけるｌｙ３１５４２０７の使用のための用量レジメン | |
| Battistin et al. | Single-photon emission computed tomography studies with 99mTc-hexamethylpropyleneamine oxime in dementia: effects of acute administration of L-acetylcarnitine | |
| CN107847504A (zh) | 淀粉状蛋白β的加兰他敏清除 | |
| AU2015258814A1 (en) | Clearance of amyloid ss | |
| JP2005523269A (ja) | 老人性うつ病の治療におけるカルニチン | |
| Huang et al. | Tau PET with 18F-THK-5351 Taiwan patients with familial Alzheimer's disease with the APP P. D678H mutation | |
| JP2021530568A5 (https=) | ||
| JP7121859B2 (ja) | 安息香酸塩または安息香酸誘導体を含む、抗ｎ－メチル－ｄ－アスパラギン酸受容体脳炎を予防または治療するための医薬組成物 | |
| JP2024508052A (ja) | 認知障害の治療のための化合物 | |
| JPS63104926A (ja) | 老年性痴呆症治療又は予防剤 | |
| JP5042425B2 (ja) | 機能性胃腸疾患治療用トラマドール |